Increased level of RPA1 and reduced level of HSPA5/GRP78 were the most prominent secretory features of vemurafenib-resistant colon cancer cells, which were also specifically correlated with BRAFV600E genotype and poor survival outcomes in colon cancer patients with BRAFV600E mutation. The gene discussed is HSPA5; the disease is malignant colon neoplasm.